Literature DB >> 18541655

Phenotypic and genotypic analyses of Neisseria gonorrhoeae isolates that express frequently recovered PorB PIA variable region types suggest that certain P1a porin sequences confer a selective advantage for urogenital tract infection.

Lotisha E Garvin1, Margaret C Bash, Christine Keys, Douglas M Warner, Sanjay Ram, William M Shafer, Ann E Jerse.   

Abstract

Typing of the porB variable region (VR) is an epidemiological tool that classifies gonococcal strains based on sequence differences in regions of the porB gene that encode surface-exposed loops. The frequent isolation of certain porB VR types suggests that some porin sequences confer a selective advantage during infection and/or transmission. Alternatively, certain porin types may be markers of strains that are successful due to factors unrelated to porin. In support of the first hypothesis, here we show urogenital tract isolates representing the most common PIA VR types identified in an urban clinic in Baltimore, MD, over a 10-year period belonged to several different clonal types, as determined by pulsed-field gel electrophoresis (PFGE). Serum resistance, which was confirmed by factor H and C4b-binding protein binding studies, was more often associated with gonococcal the most common VR types. In contrast, three porin-independent phenotypes, namely, lactoferrin utilization, beta-lactamase production, and multiple transferable resistance (Mtr), were segregated with the PFGE cluster and not with the VR type. Data combined with another PIA strain collection showed a strong correlation between serum resistance and the most common VR types. A comparison of VR typing hybridization patterns and nucleotide sequences of 12 porB1a genes suggests that certain porin loop 1, 3, 6, and/or 7 sequences may play a role in the serum resistance phenotype. We conclude that some PorB PIA sequences confer a survival or transmission advantage in the urogenital tract, perhaps via increased resistance to complement-mediated killing. The capacity of some porin types to evade a porin-specific adaptive immune response must also be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541655      PMCID: PMC2493220          DOI: 10.1128/IAI.00265-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area.

Authors:  Iona M C Martin; Catherine A Ison; David M Aanensen; Kevin A Fenton; Brian G Spratt
Journal:  J Infect Dis       Date:  2004-03-31       Impact factor: 5.226

2.  Porin protein of Neisseria gonorrhoeae: cloning and gene structure.

Authors:  E C Gotschlich; M E Seiff; M S Blake; M Koomey
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Gonococcal porin IB activates NF-kappaB in human urethral epithelium and increases the expression of host antiapoptotic factors.

Authors:  Matthew J Binnicker; Richard D Williams; Michael A Apicella
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Associations between serotype and susceptibility to antibiotics of Neisseria gonorrhoeae.

Authors:  N Woodford; K M Bindayna; C S Easmon; C A Ison
Journal:  Genitourin Med       Date:  1989-04

5.  Ability of Neisseria gonorrhoeae, Neisseria meningitidis, and commensal Neisseria species to obtain iron from lactoferrin.

Authors:  P A Mickelsen; E Blackman; P F Sparling
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

Review 6.  Recombination, repair and replication in the pathogenic Neisseriae: the 3 R's of molecular genetics of two human-specific bacterial pathogens.

Authors:  Kimberly A Kline; Eric V Sechman; Eric P Skaar; H Steven Seifert
Journal:  Mol Microbiol       Date:  2003-10       Impact factor: 3.501

7.  Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection.

Authors:  F A Plummer; J N Simonsen; H Chubb; L Slaney; J Kimata; M Bosire; J O Ndinya-Achola; E N Ngugi
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

8.  Serological classification of Neisseria gonorrhoeae with monoclonal antibodies.

Authors:  M R Tam; T M Buchanan; E G Sandström; K K Holmes; J S Knapp; A W Siadak; R C Nowinski
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

9.  Comparison of serologic and genetic porB-based typing of Neisseria gonorrhoeae: consequences for future characterization.

Authors:  Magnus Unemo; Per Olcén; Jan Albert; Hans Fredlund
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

10.  High occurrence of simultaneous mutations in target enzymes and MtrRCDE efflux system in quinolone-resistant Neisseria gonorrhoeae.

Authors:  Beti Ernawati Dewi; Sasaki Akira; Hideo Hayashi; William Ba-Thein
Journal:  Sex Transm Dis       Date:  2004-06       Impact factor: 2.830

View more
  11 in total

Review 1.  Review and international recommendation of methods for typing neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology.

Authors:  Magnus Unemo; Jo-Anne R Dillon
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

2.  Peptide Inhibitors Targeting the Neisseria gonorrhoeae Pivotal Anaerobic Respiration Factor AniA.

Authors:  Aleksandra E Sikora; Robert H Mills; Jacob V Weber; Adel Hamza; Bryan W Passow; Andrew Romaine; Zachary A Williamson; Robert W Reed; Ryszard A Zielke; Konstantin V Korotkov
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

3.  Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness.

Authors:  Douglas M Warner; William M Shafer; Ann E Jerse
Journal:  Mol Microbiol       Date:  2008-08-27       Impact factor: 3.501

4.  Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea.

Authors:  Ryszard A Zielke; Igor H Wierzbicki; Benjamin I Baarda; Philip R Gafken; Olusegun O Soge; King K Holmes; Ann E Jerse; Magnus Unemo; Aleksandra E Sikora
Journal:  Mol Cell Proteomics       Date:  2016-05-02       Impact factor: 5.911

5.  Opacity proteins increase Neisseria gonorrhoeae fitness in the female genital tract due to a factor under ovarian control.

Authors:  Jessica G Cole; Nanette B Fulcher; Ann E Jerse
Journal:  Infect Immun       Date:  2010-01-25       Impact factor: 3.441

6.  Population structure of Neisseria gonorrhoeae based on whole genome data and its relationship with antibiotic resistance.

Authors:  Matthew N Ezewudo; Sandeep J Joseph; Santiago Castillo-Ramirez; Deborah Dean; Carlos Del Rio; Xavier Didelot; Jo-Anne Dillon; Richard F Selden; William M Shafer; Rosemary S Turingan; Magnus Unemo; Timothy D Read
Journal:  PeerJ       Date:  2015-03-05       Impact factor: 2.984

7.  Functional and structural studies on the Neisseria gonorrhoeae GmhA, the first enzyme in the glycero-manno-heptose biosynthesis pathways, demonstrate a critical role in lipooligosaccharide synthesis and gonococcal viability.

Authors:  Igor H Wierzbicki; Ryszard A Zielke; Konstantin V Korotkov; Aleksandra E Sikora
Journal:  Microbiologyopen       Date:  2017-01-07       Impact factor: 3.139

8.  Lipid-Modified Azurin of Neisseria gonorrhoeae Is Not Surface Exposed and Does Not Interact With the Nitrite Reductase AniA.

Authors:  Benjamin I Baarda; Ryszard A Zielke; Ann E Jerse; Aleksandra E Sikora
Journal:  Front Microbiol       Date:  2018-11-27       Impact factor: 5.640

9.  Neisseria gonorrhoeae MlaA influences gonococcal virulence and membrane vesicle production.

Authors:  Benjamin I Baarda; Ryszard A Zielke; Adriana Le Van; Ann E Jerse; Aleksandra E Sikora
Journal:  PLoS Pathog       Date:  2019-03-07       Impact factor: 6.823

10.  Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops.

Authors:  Jessica G Cole; Ann E Jerse
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.